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PREFACE
Vascular smooth muscle cells(VSMC) are the major cell type in the tunica media of the aorta.
The many layers of the smooth muscle cells intertwined in the extracellular matrix provide structural
integrity to the vessel wall. Smooth muscle cells maintain the caliber of the blood vessel by maintaining a
contractile phenotype and secreting the extracellular matrix under normal physiological conditions. These
cells are special, as they are not terminally differentiated. Under injury or cellular stress condition, they
can switch from the contractile phenotype to a proliferative phenotype referred to as the synthetic
phenotype. This switch, called the phenotypic modulation is accompanied by loss of contractile markers
like smooth muscle α actin, myosin heavy chain and SM22α and increased deposition of the extracellular
matrix components. This repair process often turns pathogenic and leads to apoptosis of the smooth
muscle cells.
Though many different signaling pathways have been elucidated, there still exists a knowledge
gaps in linking the various signaling processes to the phenotypic modulation, with endoplasmic reticulum
stress being a comparatively new player in the field of cardiovascular diseases. Our preliminary data
showed that Sm22α was one of the most downregulated genes in this stress response. SM22α is also
known to be downregulated in various cardiovascular diseases like aneurysm and atherosclerosis, which
supports the need to study its regulation in detail under the stress conditions. We studied ER stress and
SM22 in aortic aneurysm background as it includes atherosclerosis as a pathological manifestation and
downregulation of SM22α. We used in vivo, ex vivo and in vitro techniques to study SM22’s protective
role and the mechanism under ER stress.
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CHAPTER 1: INTRODUCTION
1. Aortic aneurysm
Aorta is the largest blood vessel in the body, carrying oxygenated blood. Aneurysms occurring in
the aorta are called aortic aneurysms. Aortic aneurysm and dissections are a major cause for mortality,
responsible for nearly 14,000 deaths in the US every year[1]. An aneurysm is a permanent focal dilatation
of an artery to 1.5 times its normal diameter[2]. Depending on the region of the aorta that it occurs, they
are identified as thoracic (TAA) or abdominal aneurysm (AAA). AAA represents most of the aneurysms
that occur. TAA are rare and have a strong familial inheritance pattern. Syndromes associated with
aneurysm include Marfan syndrome(MFS), familial thoracic aortic aneurysms and dissections (TAAD),
Ehlers-Danlos syndrome (EDS), Loeys-Dietz syndrome (LDS), bicuspid aortic valve (BAV), and
neurofibromatosis type 1 (NF1)[3]. The pathophysiology of aneurysms is defined by degradation of the
vessel vasculature and loss of smooth muscle cells. The role of matrix metalloproteinases in the
extracellular matrix degradation is well studied [4-6]. The weakened vessel is hence predisposed to
dilation and rupture. The loss of smooth muscle cells in the aneurysmal tissue is attributed to apoptosis
probably from elevated levels of ROS and DNA damage[7].The smooth muscle cells also repress the
expression of the contractile genes and undergo a change in phenotype. This phenotypic switch might be
the deciding factor for the cell survival. Mechanisms associated with this switch may hold the key to
inhibit smooth muscle loss in the aneurysm tissue.
2. Vascular smooth muscle cells in cardiovascular diseases and the role of phenotypic modulation.
Vascular smooth muscle cells (VSMCs) are specialized cells that maintain the balance between
vasoconstriction/vasodilation for the smooth functioning of the blood flow distribution. SMCs in the adult
blood vessel possess a low rate of proliferation and express a unique repertory of contractile genes and
signaling molecules that confers the ability to maintain the contractile phenotype[8]. VSMCs possess the
ability to change their contractile phenotype to a synthetic phenotype. This switch is called phenotypic
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modulation. The synthetic phenotype is characterized by an increase in proliferation, migration and
increased synthesis of extracellular matrix[9]. The cells respond to a wide range of vasoactive stimuli by
switching phenotype during pathology. Teleologically, this plasticity was probably a survival response to
injury and stress. Under most pathological conditions though, this plasticity predisposes the cells to
detrimental signaling and progression of vascular diseases. VSMC phenotypic modulation is a defining
feature of many cardiovascular pathologies like aneurysms[10-12] and atherosclerosis[13-15]. One of the
hallmark features of the synthetic or dedifferentiated phenotype is the loss of contractile markers like
smooth muscle α actin, myosin heavy chain and SM22α [9]. Advances in the clinical and animal model
studies have identified the synthetic phenotype in a wide range of pathologies like arteriopathy of diabetes
and chronic kidney diseases[16-18]. The dedifferentiated cells depending on the environment may acquire
additional phenotypic changes making them inflammatory[19, 20], adipogenic[16], osteogenic[16, 21] or
osteochondrogenic[16, 21]. This pathogenic phenotype comes as a drawback for the high plasticity that
these cells possess.
Research by previous lab members have helped establish the fact that the downregulation of the
contractile gene expression plays an active role in the pushing the cells towards the pathogenic
phenotype[22, 23]. My work aims at studying the regulation of one such contractile gene Sm22α during
endoplasmic reticulum(ER) stress response(Fig.1).
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Figure 1 Vascular smooth muscle cells undergo phenotypic modulation in the cardiovascular
diseases including aortic aneurysm.Vascular smooth muscle cells(VSMCs) are characterized by
high expression of contractile marker genes.VSMCs are not terminally differentiated and undergo
phenotypic modulation under many pathological conditions.The synthetic phenotype is marked by
reduced expression of the smooth muscle markers and increased expression of inflammatory and
osteogenic marker genes. The cells transform from spindle shaped to a cobblestone morphology.The
cells also becomes more proliferative and migratory.(https://www.nhlbi.nih.gov/health/healthtopics/topics/arm/types)

3. Cytoskeleton, Extracellular matrix and aortic aneurysm
In addition to their contractile capacity, VSMCs possess important secretory properties that
ensure the synthesis and repair of various ECM components that regulate the structure of the vascular
wall (collagen, elastin, fibrillin, fibronectin). Importantly, VSMCs can interact directly with the different
ECM components through cell-surface integrin receptors, G-protein-coupled receptors and the discoidin
domain receptor family. The fundamental unit of the cytoskeleton--cell receptor--ECM complex regulates
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the function of the aortic wall. Indeed, VSMCs can transform mechanical stimuli into biological
responses (also known as mechanotransduction), leading to intracellular responses (cytoskeletal
rearrangement and stress fiber alignment) and extracellular changes (synthesis, alignment and repair of
ECM components) that, in turn, can communicate directly with the cell.[24-27]. Mechanical stimuli are
transmitted via integrins from the elastin to the intracellular compartment, which can lead to activation of
biochemical signal activation and contraction of the contractile unit. The extracellular matrix has an
important and complex function in maintenance of the integrity of the aortic wall. Elastin and its
associated microfibrils interact with SMCs as described herein, but elastin also plays a critical role in
regulation of the development of the aorta. The extracellular matrix also contains microfibril-associated
proteins, such as fibulin or latent transforming growth factor (TGF)-β1 binding protein, which play a vital
role in sequestration and regulation of the activity of cytokines, such as TGF- β [25, 28].Collagen fibers,
primarily type I and III collagen, are also present in the aortic media and contribute to the stiffness of the
aorta.
At the cellular and molecular level, the ability of the aortic wall to sense biomechanical forces via
its unique cell-matrix interactions has an important bearing on its structural integrity and development.
The aortic wall is constantly exposed to cyclic mechanical loads from pulsatile blood flow, with the
ascending aorta exposed to forces delivered by the beating heart. Genetic mutations that affect
mechanosensing via the elastin-contractile unit lead to aneurysm. Elastin, collagen fibers and the
extracellular matrix (ECM) endure the bulk of stress that is exerted on the aortic wall, which is typically
100-200 kPa, such that only 3-5 kPa is exerted on the SMCs in the aortic wall. SMCs sense this stress via
the elastin-contractile unit and regulate and remodel the ECM. In essence, the SMCs sense and monitor
the mechanical stress of the aortic wall constantly via their contractile thin and thick filaments and
integrin receptors and accordingly alter their cytoskeletal structure and the composition of the ECM via
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various signaling cascades. Phenotypically modulated VSMCs are characterized by change in their
secretory function. This change contributes to the pathology of the aneurysm tissue.
4. SM22α and its role in pathology of vascular diseases
SM22α or transgelin is a 22kDa protein was first identified in the chicken gizzard smooth
muscle[29]. Its known to be expressed abundantly in the smooth muscle cells and at detectable levels in
the fibroblasts. SM22 has two other homologs SM22β (transgelin 2) and NP22 (transgelin 3/Neuronal
protein 22). All the homologs are cytoskeletal protein, but they express in different cell types[30, 31].
SM22β expresses in the smooth muscle and endothelial cells[30] whereas NP22 expresses in the
neurons[31]. Structurally SM22 belongs to the calponin protein family. It has a N-terminal calponin
homology domain(CH) and a C-terminal calponin like repeat. The protein structure has potential binding
sites for calcium and phosphorylation sites[32]. The crystal structure was described by Li et
al[33].SM22’s role as an actin binding protein has been well characterized[34, 35].
Expression of SM22α has been reported to be downregulated in a variety of carcinomas like
prostate cancer[36], breast cancer and colon cancer[37, 38]. SM22α’s expression is also downregulated in
cardiovascular diseases like aortic aneurysm[39] and atherosclerosis[40] as part of the phenotypic
modulation of the smooth muscle cells. Sm22s role in modulating contractility in the SMCs is shown in
Sm22 knockout mouse model[41, 42]. Sm22-/- mice on the contrary have normal blood pressure, heart
rate and vascular morphology[43]. SM22 is thus thought to be compensated under homeostasis but may
play a role in a stress condition. My work focuses on regulation of SM22α under ER stress. ER stress is
reported to be activated in cardiovascular diseases like atherosclerosis[44], aortic aneurysm[45] and
vascular calcification[46, 47].
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5. Endoplasmic reticulum stress and Cardiovascular diseases:
The ER stress is the cellular stress response associated with the functioning of the ER. The
endoplasmic reticulum is an organelle required for many essential processes in the cell including protein
synthesis, post translational modifications, synthesis of phospholipids and steroids, regulation of calcium
homeostasis and many more[48]. The ER is a dynamic organelle and interacts with a wide range of other
organelles including Golgi[49],Mitochondria [50],the Plasma membrane[51] and Nucleus. Disturbances
in any of the major functions mainly the protein folding leads to a stressed ER. The stress caused due to
unfolded proteins, triggers a series of signaling cascades termed the Unfolded Protein Response(UPR)
[52].ER stress has been shown to be required for many physiological processes like insulin secretion from
pancreatic β cells[53] and osteoblast maturation during bone formation[54, 55]. The UPR activation
involves 3 distinct steps:1) Attenuation of protein translation to avoid buildup of misfolded proteins 2)
Activation of chaperones to help fold the misfolded proteins 3) Activation of ER associated degradation
to degrade the proteins whose structure cannot be rectified. The signaling is a 3-pronged cascade
involving PERK (pancreatic ER kinase), IRE1 (inositol-requiring transmembrane kinase/endonuclease 1),
and ATF6 (activating transcription factor 6). Prolonged interaction of the protein folding system with the
chaperones activates the downstream apoptotic signaling(Fig.2).
Presence of ER stress has been established in a wide range of clinical and animal model samples
of vascular pathologies. Many compounds have been identified that could block atherosclerosis induced
ER stress. Treatment with some of these compounds were shown to have therapeutic benefits[56, 57].
Deletion of myocardin – a transcriptional co-activator caused aortic aneurysm accompanied by ER
stress[58]. Another study showed deletion of Chop, a signaling molecule of the ER stress process
prevented aortic aneurysm[59].Attenuating ER stress have been shown to reduce vascular calcification
[60-62].A recent review discusses

ER stress in cardiovascular disease in detail[63]. However, the

mechanism of the stress response and vascular remodeling is unclear and needs to be elucidated in detail.
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Figure 2 Unfolded protein response of the ER has two responses -the adaptive and the apoptotic
UPR. An overload of unfolded proteins triggers the detachment of the ER chaperone Bip from the ER
stress transducers and Bip binds to the unfolded proteins. The 3 transducers IREα, ATF6 and PERK
activate downstream signaling. All the 3 arms of signaling cause nuclear translocation of factors that
induce gene expression of adaptive response genes. Persistent stress then leads to activation of proapoptotic genes. Upon ER stress IREα, oligomerizes and undergoes autophosphorylation. It cleaves
XBP1 and its spliced form enters the nucleus. ATF6 undergoes cleavage in Golgi and enter the
nucleus. PERK also oligomerizes and auto phosphorylates like IREα. PERK then phosphorylates
elF2α leading to increased expression of ATF4. ATF4 translocated to the nucleus and induces the
expression of pro-apoptotic factors like CHOP. Phosphorylation of elF2α also leads to activation of
NF-kB.
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CHAPTER 2 - RESULTS
I. Establishing ER stress and apoptosis in the aortic aneurysms of Sm22-/- Marfan mouse model
1. Background
1.1 Marfan Syndrome (MFS)
Marfan syndrome is one the genetic disorders whose cardiovascular manifestations include
aortic aneurysm. Marfan syndrome is an autosomal-dominant inherited disease affecting ~1 in 5000
births[64]. Mutation in Fibrillin-1(FBN1) gene is known to cause (MFS). Fibrillin-1 is one of the
component of the cellular architectural matrix. Its two major roles in the context of aneurysm include
– providing tensile strength to the cell and regulating the bioavailability of the cytokine, Transforming
growth factor beta (TGFβ) via its interaction with latent TGFβ binding proteins (LTBPs)[65]. The
fibrillin microfibrils can exist as individual structures or associate with elastin to form macroaggregates. These elastic assemblies are important to carry out the physiological function like
maintain the cardiovascular tone[66].Mutations in the Fibrillin gene leads to a compromised elastic
assembly, predisposing the vasculature to structural incompetency. The defective fibrillin also causes
increase in the TGFβ in the cell. TGFβ dependent increases in MMP2/9 leads to further breakdown of
the extracellular matrix[67]. Role of TGFβ in the disease pathogenesis of MFS was established with
help of the Marfan mouse model. The mouse had a heterozygous mutation for the Fbn1 gene
(Fbn1C1039G/+)[68].
1.2 Marfan - Sm22-/- mouse model
SM22 expression has been shown to be downregulated in the aneurysm tissue. Our lab made
a Sm22 deletion in the Marfan mouse to generate a Fbn1C1039G/+: Sm22-/- mouse model. We observed
increased severity of aneurysm formation in these mice (Fig.3) We used these mice to test for smooth
muscle apoptosis and presence of increased ER stress signaling by histopathology.
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Figure 3: Aneurysm mouse model: SM22 deficiency exacerbated the aneurysm
formation in Marfan mouse (Fbn1C1039G/+). Upper panel: Left -Right: normal aorta from
Sm22-/- mice, normal aorta from Marfan mouse. Lower panel: Colored arrows indicate the
Thoracic aneurysm closer to the heart and Abdominal aneurysm in the lower part of the
aorta from Fbn1C1039G/+: Sm22-/- mouse. SM22 deficiency leads to a higher incidence and
severity of aneurysm in the MFS mice. Picture credits: Dr. Xiaohua Dai, Li Li lab

1.3 Significance of Ex vivo culture system
Ex vivo culture system refers to isolation of organs from the organism and culturing them in an
external environment with minimal alterations of natural conditions. The advantage of this system lies in
the fact that it allows the cells to be in their natural setting. In aorta, it allows the cells to maintain the
structural scaffolding with the ECM. It helps reduce the non-aortic signaling crosstalk.
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1.4 Pharmaceutical ER stress inducers
There are several chemicals used regularly to induce ER stress. These include tunicamycin,
brefeldin A and thapsigargin. All of them induce unfolded protein response (UPR) in the ER by creating
an unfolded protein overload through various mechanisms. Tunicamycin blocks the initial step of
glycoprotein biosynthesis by inhibiting the enzyme UDP-N-acetylglucosamine-dolichol phosphate Nacetylglucosamine-1-phosphate transferase (GPT). Brefeldin A causes accumulation of unfolded protein
by inducing retrograde protein transport from the Golgi to the ER and blocking transport of proteins from
the ER to Golgi. Thapsigargin works by decreasing ER store calcium and increasing the cytosolic calcium
levels in the cell. It does this by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ATPase(SERCA) which sequesters calcium from the cytosol, thereby raising intracellular calcium. Store
depletion also secondarily activates plasma membrane channels and causes more influx of calcium into
the cytosol. As the calcium levels in the ER decrease, the calcium dependent chaperones of the ER lose
their activity and hence can no longer fold the protein. This leads to overload of unfolded proteins[69,
70].Thapsigargin has been shown to induce apoptosis[71, 72]. We selected thapsigargin as it induces
apoptosis, which was the hypothesized endpoint of the cells in our aneurysm model.
2. Results
2.1 Aneurysm tissue from the Fbn1C1039G/+: Sm22-/- mice stained positive for apoptosis
The aneurysm tissue from the Fbn1C1039G/+: Sm22-/- mouse was used to perform the TUNEL assay
to establish apoptosis. TUNEL assay stands for Terminal deoxynucleotidyl transferase (TdT) dUTP NickEnd Labeling. TdT is a specialized DNA polymerase and is capable of labelling blunt ends of double
stranded breaks. The assay uses this ability to label apoptotic cells that undergo severe DNA degradation
as part of the apoptosis mechanism. The aneurysm tissue was found positive for higher number of
apoptotic cells compared to the aortic tissue from the WT mice (Fig.4). Extensive degradation of the
elastin layers can be observed in the aneurysm sample.
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Figure 4: VSMCs undergo apoptosis in aortic aneurysm tissue from Fbn1C1039G/+: Sm22-/- mouse.
The apoptotic cells are detected by TUNEL assay. Terminal deoxynucleotidyl transferase (TdT) is
a specialized DNA polymerase and is capable of labelling blunt ends of double stranded breaks.
Multiple clinical studies have shown presence of apoptotic VSMCs in the aneurysm samples. Upper
panel: Aorta tissue from WT mouse. The structural integrity of the elastin fibers can be seen by
distinct layers. Lower panel: Aorta from Fbn1C1039G/+: Sm22-/- mouse. The aorta tissue from these mice
undergo extensive degradation. This leads to loss of distinct elastin membrane layers. The black
arrows point to apoptotic cells.

2.2 Aneurysm tissue from the Fbn1C1039G/+: Sm22-/- mice stained positive for ER stress markers.
We stained the tissue for Activating transcription factor 4 (ATF4). It is downstream in the PERK
arm of the ER UPR signaling pathway. We found that the tissue stained positive for higher ATF4
showing activated ER stress in the aneurysm tissue (Fig.5). We then stained for CHOP, a pro-apoptotic
factor downstream to the ATF4. CHOP expression was also upregulated in the aneurysm tissue (Fig.6).
This showed that ER stress induced apoptosis was being induced in the aneurysm tissue.
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Figure 5: Upregulated ATF4 expression was observed in aneurysm tissue from Fbn1C1039G/+:
Sm22-/- mouse by IHC: (L)Aortic tissue from WT mouse. (R) Aortic tissue from Fbn1C1039G/+: Sm22-/mouse. N=3Activating transcription factor 4 (ATF4) is upregulated by phosphorylated elF2α. It
translocates to the nucleus to induce transcription of adaptive genes. In chronic ER stress Atf4 induce
the pro-apoptotic factor Chop. N=3

Figure 6: Upregulated CHOP expression was observed in aneurysm tissue from Fbn1C1039G/+:
Sm22-/- mouse by IHC: Left panel: Aorta from WT mouse. Right panel: Aorta from Fbn1C1039G/+:
Sm22-/-.CHOP (GADD153) is ubiquitously expressed at very low levels in the cells. Under nonstressed conditions, it is present in the cytosol. Robust stress conditions induce elevated levels of
CHOP and its accumulation in the nucleus. N=3
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2.3 Sm22α deficiency results in a higher ER stress response in the ex vivo model of aorta culture
After the activation of ER stress markers were confirmed by immunohistochemistry in the
aneurysm tissue, we carried out an ex vivo aorta culture. We wanted to test the significance of Sm22
deficiency in the ER stress process. To test this, we used aorta from WT, Sm22+/- and Sm22-/- mice. The
aortas were isolated and incubated in culture medium containing thapsigargin. After 24 hrs. of incubation
RNA was isolated to perform qPCR analysis for the expression of Atf4 and Chop. We found that Sm22α
deficiency caused a higher expression of Atf4 and Chop (Fig.7).
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6
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Figure 7 Higher expression of Atf4 and Chop in Sm22 deficient mice aorta- an ex vivo model. A)
Atf4 expression by qPCR assay was found to be higher in aortas with Sm22 deficiency. B) Chop
expression by qPCR assay was found to be higher in aortas with Sm22 deficiency. Aortas were
isolated form WT, Sm22+/- and Sm22-/- mice. The aortas were then incubated in culture medium with
thapsigargin for 24 hrs. at 37C. RNA was isolated, and qPCR was performed. Atf4 is downstream to
Perk and elF2α. The Perk pathway is considered to be the apoptotic arm of the ER-UPR signaling. In
the initial stages ATF4 upregulates expression of adaptive genes to resolve stress. Once the balance
shifts towards apoptosis, ATF4 induces the expression of Chop. Chop is a pro-apoptotic factor that
induces the expression of apoptotic factors downstream. -/- mice. N=3, *** indicated P value <0.001.
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3. Discussion
Apoptosis of smooth muscle cells is thought to the primary reason for smooth muscle cell loss in
aneurysm[73, 74].Among the many stress signals activating apoptosis, ER stress is the lesser known
pathway in aneurysm. A few studies have shown activation of ER stress in Ang II or Cacl2 induced
aneurysm[45, 75, 76].Consistent with these studies we show presence of ER stress induced apoptosis in
our mouse model. This also points to the association of ER stress with aortic aneurysm irrespective of the
etiology. The results also highlight the role of Sm22α under stress. It suggests that under quiescent
conditions Sm22α might be compensated but it may play an active role in stress conditions
II. ER stress triggers a signaling cascade inducing phenotypic modulation leading to apoptosis in
smooth muscle cells
1. Background
The cells need protein homeostasis or proteostasis to maintain optimal functioning of the cells in
response to various stimuli. Hence the cells have a very sophisticated mechanism of sensing cell changes
and responding to it. There exists an intricate network of cytosolic proteostasis and organelle proteostasis
that work together to reduce proteotoxic stress. The cytosolic proteostasis include the chaperones like the
heat shock proteins to fold the proteins and degradation system like the proteasome pathway to
unfavorable proteins. The organelle proteostasis include the ER. The ER keeps its protein folding in
check using the unfolded protein response (UPR). The homeostasis is maintained by the adaptive
response of the UPR. This function of the UPR tries to resolve the protein overload by increasing the
expression of the protein folding chaperones. The predominant function of the UPR is to maintain the cell
function and structure in response to stress. Once the adaptive response proves insufficient to maintain
normal functioning, the apoptotic UPR signaling is triggered. The main function of this signaling is to get
rid of the cells whose normal functioning cannot be restored. Cells subjected to severe or chronic stress
are cleared through this pathway[77]. The trigger, signaling the switch from adaptive to apoptotic remains
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unclear. Although in most cases, once the balance shifts to apoptotic pathway, several pathogenic
signaling are also induced.
The role of long term ER stress has been suggested in the inflammatory and osteogenic signaling
in many pathologies[63]. There is some research though that suggest that ER stress has an antiinflammatory role[78]. Our work aims at highlighting the regulation of cytoskeletal markers in the
context of ER stress and its associated signaling. SM22α and SMAα are the characteristic cytoskeletal
proteins of the smooth muscle cell. The most well elucidated gene regulatory mechanism of the smooth
muscle genes is through SRF/myocardin ternary complex. SRF along with the its transcriptional coactivator myocardin binds to the CArG boxes in the promoter of the cytoskeletal gene to induce its
expression. There are many ternary complex factors that compete with the SRF/myocardin complex to
repress the transcription.
We treated our cells with 2 pharmaceutical ER stress inducers- 1) tunicamycin (Tm) 2)
thapsigargin (Tg) and found that they produced similar preliminary results. We chose to continue our
work with thapsigargin as it causes ER stress through changes in intracellular calcium. Perturbed calcium
signaling has been implicated in aneurysm pathology[79].Also changes in calcium levels lead to vascular
calcification through matrix vesicle release by synthetic VSMCs[80].
2. Results
2.1 Chronic ER stress causes a transient upregulation of SM markers

The smooth muscle cell line was treated with thapsigargin for up to 24hrs. We observed the
expression pattern of Sm22α and Smaα over the course of 24 hrs. We found that the gene expression was
transiently upregulated before downregulating (Fig.8). Calponin1(Cnn1), Sm22α, Smaα were among the
most downregulated cytoskeletal genes. The other smooth muscle genes that were downregulated at the
24hr time point were vimentin (Vim), Filamentin A(Flna), Myocardin (Myocd), Myosin heavy chain
(Myh11), Tubulin beta (Tubb) and Transgelin 2 (Tagln 2) (Fig.10). The activation of ER stress was
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confirmed by the upregulation of of ER stress markers Atf4, Chop (Fig.9 and Fig.11). It was
accompanied by upregulation of Klf4 and Pdgf-bb expression.ER stress chaperones Calr and Grp78(Bip)
were also found to be upregulated. Tunicamycin and thapsigargin resulted in downregulation of Sm22α to
a similar extent. Thapsigargin treatment also caused downregulation of ECM markers – Collagen (Col3a),
Fibrillin(Fbn1) and Fibronectin(Fn1) (Fig.10).
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Figure 8: Thapsigargin treatment caused transient upregulation of smooth muscle markers.: A)
Time dependent gene expression pattern of Sm22 by qPCR assay with thapsigargin treatment. B) Time
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C) Western blot showing upregulation of SM22 at 6 hrs. with thapsigargin treatment. Upregulation of
protein was only detected at 6hrs and not at 1-3hrs. Translation follows transcription and delay between
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indicative of the adaptive response of the ER-UPR. Loss of smooth muscle markers induce phenotypic
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proteins probably marks the transition of the adaptive response to the apoptotic branch of the
signaling.SM22 and SMA are the two characteristic markers of smooth muscle phenotype. N=3-6, P
value *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively vs the control(cntrl)
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2.2 ER stress induces an upregulation of transcription factor Klf4 and Mmp9
ER stress induced the expression of Klf4, Pdgf-bb and Mmp9(Fig.12). We found that Klf4 and
Pdgf-bb expression is upregulated as soon as 1hr of thapsigargin treatment (Fig.9). The phenotypic
marker Pdgf-bb is known to induce expression of Klf4 through Sp1 binding to the Klf4 promoter.
Traditionally Klf4 is known to repress the transcription of smooth muscle markers. Recent studies
however show that the post translational modification of Klf4 determines its function as enhancer or
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repressor. The non SUMOylated Klf4 is known to induce the expression of smooth muscle genes whereas
the SUMOylated form represses the SM gene expression. This is probably why we see an increase in the
smooth muscle genes accompanied by increase in Klf4 expression. KLF4 is known to repress the
expression of smooth muscle markers through several mechanisms. KLF4 binds the CArG box in the
Sm22 promoter replacing the Sm22 inducing SRF-MYOCD complex. It also recruits HDAC2 to block the
SRF complex from binding the promoter. KLF4 also represses the expression of smooth muscle master
regulator MYOCD. MMP upregulation is characteristic of the aneurysm and atherosclerosis pathology. It
is responsible for the degradation of the vessel wall. Apart from repressing the gene expression of the
ECM genes, ER stress also degrades the vessel wall by inducing expression of Mmp9
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Figure 12: Thapsigargin treatment (24 hrs.) caused upregulation of Klf4 and Mmp9. In PAC1
cells treated with thapsigargin for 24 hrs. A) qPCR showed upregulation of Klf4 and Mmp9. B)
Western blot assays showed the upregulation of KLF4. N=3-6, P value * and *** indicate p<0.05 and
p<0.001 respectively vs the control(cntrl).

22

2.3 ER stress induces inflammation and osteogenic markers
Thapsigargin treatment induced the inflammation markers Vcam-1 and Ccl2 in the smooth muscle
cells. Along with markers of inflammation, osteogenic markers were also upregulated. The osteogenic
genes whose expression was increased were Pit-1, Runx2, Msx2 and Ocn (Fig.13). Some these markers
are known to bind to Sm22α promoter directly or displace the SRF/MYCOD to repress Sm22α expression.
Runx2 is a transcription factor whose targets include Ocn. Msx2 is also a transcription factor contributing
to the vascular calcification. Runx2 and Msx2 regulate expression of many ECM genes. Pit-1 is a sodium
dependent phosphate transporter whose expression along with Runx2 and Ocn is mediated by the ER
stress induced transcription factor Atf4. Spliced XBP1 is also known to mediate Runx2 expression.
Thapsigargin also induced apoptosis at the same time point (Fig.14)
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2.4 Effect of physiological ER stress inducers on VSMCs
Free fatty acids (FFA) is one among the many risk factors for the cardiovascular diseases and
elevated FFAs have been shown to be associated with increased aortic stiffness, seen in
atherosclerosis[81, 82].Palmitate, a saturated fatty acid accounts for 30-40% of the serum FFAs. Palmitate
has been shown to alter the extracellular matrix in cultured smooth muscle cells, causing lipoprotein
deposition and favoring atherogenesis [83]. Palmitate is also known to induce various cellular stress
responses like endoplasmic reticulum (ER) stress, phenotypic modulation and apoptosis[84, 85]. We
found that palmitate like thapsigargin induced downregulation of smooth muscle markers along with
upregulation of Mmp9 and Chop (Fig.15). It is possible that the phenotypic modulation caused by
palmitate is due to its induction of ER stress in the VSMCs. Further analysis is needed to elucidate the
mechanism.
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3 Discussion
Our results consolidate the data that ER stress induces a cascade of pathogenic signaling
pathways that lead to downregulation of smooth muscle markers leading to phenotypic modulation of
VSMC. These smooth muscle cells in the synthetic state then progress to apoptosis. The results show that
a range of factors induced as part of the ER stress response further induce factors that trigger
inflammation and osteogenesis. The numerous factors involved in these processes have been shown to
downregulate the smooth muscle marker SM22α in several ways[86-90]. Sm22α was found to be one of
the most downregulated genes in the stress response. SM22α is also known to be downregulated in
various cardiovascular diseases like aneurysms[39, 91] and atherosclerosis[40, 92, 93] , making it an ideal
candidate for further analysis. Our results show upregulation of both phenotypic markers Pdgf-bb and
Klf4. Pdgf-bb is known to be a potent repressor of SMC genes. Part of its repressor function is shown to
be mediated through upregulation of Klf4 expression. The phenotypic marker Kruppel like factor 4
(KLF4) has been shown to downregulate the Sm22 expression through a few different mechanisms. Klf4
can bind to the two distinct regions of the Sm22 promoter and recruit HDAC2 to interfere with Srf/Myocd
dependent transcription. KLF4 also represses the expression of Myocd, hence limiting its availability for
Sm22 expression[86-88]. The transcription factor ATF4 (PERK pathway) has been shown to upregulate
KLF4 by increasing its transcription and blocking its protein degradation.
The Perk pathway is also involved in triggering NF-kb mediated inflammation which represses
Sm22α transcription. The nuclear factor NF-kB induces a repertoire of pro-inflammatory genes which
include cytokines, chemokines and adhesion molecules. Under normal conditions NF-kB is bound by the
inhibitory molecule IkBα. PERK induced phosphorylation of eIF2α which induces a translational
repression to combat ER overload. This repression leads to reduced IkBα leading to less sequestration of
NF-kB. The free NF-kB then translocates to the nucleus to induce expression of inflammatory markers
like Vcam-1, Ccl2 etc. NF-kB has also been shown to bind to CArG box of Sm22α promoter and repress
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its transcription. A parallel signaling involves degradation of IkBα through IKKα enzyme. IRE1
dependent regulation of the IKKs basal activity through TRAF2 plays a vital role in IkBα reduction under
ER stress[94, 95].
ER stress induced transcription factors ATF4 and CHOP have also been implicated in vascular
calcification[47, 96].Vascular calcification is the most extreme form of phenotypic modulation in
SMCs.RUNX2 an osteogenesis specific transcription factor upregulated in two different arms of the ER
stress response ATF4(PERK pathway) and XBP1(IREα pathway).RUNX2 interacts with SRF thus
blocking the SRF/MYOCD complex binding on CArG and repressing SM22α transcription[90]. Another
osteogenic factor involved in SM22α downregulation is PiT-1[97].ATF4 and CHOP (PERK pathway)
have been shown to regulate type III sodium-dependent phosphate cotransporter, PiT-1 expression
through interaction with C/EBPβ[47, 89]. Pit-1 has been shown to repress SM22α by methylating its
promoter[98]. Pit-1 is also known to regulate RUNX2 too, thus amplifying the osteogenic
effect[99].Palmitate has been implicated in cardiovascular diseases. We show that palmitate has the same
effect on cytoskeletal markers as thapsigargin. Hence it might be that the phenotypic modulation and
inflammation caused by palmitate is partly through the ER stress process.
III Mutational analysis of Sm22α promoter under ER stress
1. Background
Sm22α is a 5.4 kb gene located on 11q23.2. It has 5 exons, 1 large and 3 small introns. Cis
regulatory elements in the Sm22 promoter include two CArG boxes (near and far), Smad binding element
(SBE) and TGFβ control element (TCE) (Fig.16). Our lab made a series of promoter mutations based on
these different cis regulatory elements[100]. Many factors induced during inflammation and calcification
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have been shown to regulate Sm22α expression. To check which binding sites of the promoter was
involved in its downregulation under ER stress, luciferase assay was carried out to check for SM22α
expression in cells transfected with different mutants and treated with thapsigargin. Myocardin is the
master regulator of SM22α expression [101], so we overexpressed Myocardin to see if it could rescue the
downregulation of SM22α.

Figure 16: Graphical representation of the Sm22α gene-Cis and Trans elements. The Sm22α gene
is 5.4 kb and located on 11q23.2. It has 5 exons(boxes) and 4 introns(lines) with intron 1 being the
largest. Several putative promoters are present in the 800bp upstream region. A 1566 bp transcript is
generated. Entire exon 1, 12 bp of exon 2 and last 432 bp of exon 5 are untranslated. CArG- serum
response binding box, TCE- TGFβ control element, SBE- SMAD binding element. Figure adapted
from Gary K. Owens, Meena S. Kumar, Brian R. Wamhoff Physiological Reviews Published 1 July
2004 Vol. 84 no. 3, 767-801 DOI: 10.1152/physrev.00041.2003 and Assinder, S TAGLN(transgelin)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(6):477-479.
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2. Results
The different plasmid constructs that were used include a full length Sm22 promoter, SBE mutant,
TCE mutant, CArG near mutant, CArG far mutant, CArG null-TCE mutant and SBE alone. The cells
were transfected with these plasmids and treated with thapsigargin(Fig.17). We found that SM22
downregulated in all the cases showing that all the different sites were involved in its repression. SBE site
was found to be sufficient to repress the expression of SM22 with thapsigargin. Many transcription
factors induced by ER stress have been shown to bind Sm22 promoter and cause its repression.
As myocardin can stimulate Sm22 expression through different promoter mutants, we wanted to
test if it could stop SM22 downregulation in an analogous manner using the luciferase assay We tested to
see if myocardin overexpression could rescue SM22 downregulation under thapsigargin treatment. We
found that myocardin overexpression could reduce the downregulation of SM22 in all the cases except
when CArG far was used. This can be explained by the fact that myocardin induces SM22 at very low
levels through this mutation. Hence a significant change in regulation could not be observed.
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Figure 17: Promoter analysis by luciferase assay shows more than one cis element of Sm22 is
involved in its downregulation under ER stress. Luciferase assay was carried out using the
different promoter mutants. No single or double mutant could prevent SM22 downregulation with
thapsigargin treatment. It can be inferred that more than one cis element is involved. The data is
backed by literature showing various trans elements induced by ER stress capable of binding different
regions of the Sm22 promoter and repressing its expression. Various promoter mutation plasmids with
luciferase were transfected into PAC1 cells A) A full length Sm22 promoter was used. B) Promoter
with mutation in the smad binding element (SBE) is used. C) Promoter with mutation in the TGF
control element (TCE) is used. D) Plasmid construct with only the SBE site was used. E) Promoter
with mutation in the CArG near region was used. F) Promoter with mutation in the CArG far region
was used. G) Promoter with double mutation in the CArG and TCE region was used. Myocardin is
known to induce SM22 expression through all these promoter mutants. The same effect was observed
even with thapsigargin treatment. Overexpression of myocardin can block SM22α downregulation to
some extent under the ER stress condition. N=3

3. Discussion
A consensus sequence motif of nucleotides that form a signal is called a box. The sequence with
the nucleotides [CC(A/T)6GG] is referred to as the CArG box. Almost all the smooth muscle gene
promoters have been shown have at least two of these. The CArG boxes play a pivotal role in their
transcription. SRF has been shown to bind the CArG box selectively in SMCs and myocardin increased
SRF binding. The binding of the SRF/myocardin complex to the promoter requires some epigenetic
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modifications. Myocardin/SRF complexes physically interact with H3K4dMe and is sensitive to
expression levels of myocardin. As expression of myocardin is reduced under ER stress, the SRF binding
to the chromatin is reduced thus repressing Sm22 expression. Parallelly, Klf4 induced under ER stress can
bind the TCE site on the promoter and recruit histone H4 deacetylase to compact the chromatin and
render the CArG box inaccessible to SRF[102]. Myocardin binds to SMAD3 and coactivates the Sm22
expression via the SBE site. Hence the repression of SM22 expression through this site is caused by
reduced myocardin availability[103]. NF-kB is also known to bind myocardin preventing the
SRF/myocardin complex from binding to the CArG box[104]. RUNX2, induced during ER stress also
binds SRF and inhibits SRF dependent transcription[90].
Hence inhibition of SRF/myocardin complex plays a key role in Sm22 repression under ER stress.
We therefore see an increase in SM22 expression when myocardin is overexpressed. It is possible that the
ER stress induced repressors are more potent than myocardin and hence myocardin overexpression is not
sufficient to block the Sm22 repression completely.
IV. SM22α overexpression can reduce expression of inflammatory and ER stress markers
1. Background
SM22α deficiency has been shown to induce inflammation and chondrogenesis in an arterial
injury model[22, 23].As SM22α expression downregulates under ER stress, we overexpressed SM22α to
see if it could reduce the expression of inflammation, osteogenic or ER stress markers. We also
overexpressed myocardin to see if it could reduce the inflammation and osteogenesis.
2. Results
We only saw reduction in the expression of ER stress (Atf4, Chop) and inflammation
markers(Ccl2) but no change in the expression of calcification markers (Fig.18A-B). Myocardin induced
SM22 expression could only reduce Vcam-1 expression (Fig.18C). It was not enough to reduce Ccl2, Atf4
or Chop expression.
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3. Discussion:
NF-kB has also been shown to repress Sm22 expression in a CArG box dependent manner[104].
Reduced SM22α works in a loop mechanism to induce inflammation. SM22α is required to form a
complex with IKBα to sequester NF-kB. Reduced binding of SM22 to IKBα leads to more nuclear
translocation of NF-kB[105].By overexpressing SM22α, we might be reducing the nuclear translocation
of NF-kB to some extent and hence we see reduce Ccl2 expression. Reduction in inflammation probably
also lead to less ER stress shown by reduced expression of Atf4 and Chop. Myocardin could only reduce
Vcam-1 expression under ER stress.
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Figure 18: SM22 overexpression can reduce the expression of inflammation and ER stress markers.
Deficiency of Sm22 has been shown to induce inflammation and elicit a higher ER stress response. Overexpression
of SM22 by adenovirus in PAC1 cells reduced the expression of ER stress markers Atf4 and Chop. qPCR assay
showed A) SM22 overexpression reduced the mRNA expression of Atf4 and Chop under Tg treatment B) SM22
overexpression reduced the expression of Ccl-2. SM22 overexpression only reduced expression of Ccl-2 and not
Vcam-1. C) MYOCD overexpression on the contrary only reduced the expression of Vcam-1 and not Ccl-2. N= 36. P value *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively vs the control(cntrl).
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V. Cytoskeletal dynamics regulate the ER stress response
1. Background
Disruption of actin cytoskeleton has been shown to induce NF-kB nuclear translocation and
dependent inflammation induction[106, 107].Also Sm22 deficiency has been shown to collapse actin
cytoskeleton[23].Studies show that inflammation could induce ER stress[108].Hence we treated the cells
with actin depolymerizer cytochalasin D to see if it induced ER stress. We also observed changes in ECM
expression during actin depolymerization with latrunculin B. We treated the cells with CytoD and
thapsigargin to see if ER stress influences this interplay between ECM components and the cytoskeletal
dynamics.
2. Results
Cytochalasin D was sufficient to induce ER stress and when used in combination with
thapsigargin, caused a more severe stress response shown by the expression levels of Atf4 and Chop
(Fig.19 A). Depolymerizing actin with CytoD caused upregulation of expression of ECM markers like
Col3a, Fbn1 and Fn1.This upregulation of ECM proteins is blocked when treated with thapsigargin
(Fig.19 B).
3. Discussion:
SM22α has long been studied as an actin binding protein. The earliest known function was to
bind actin and help in the formation of cytoskeletal structures like stress fibers[34].Follow up studies
showed that SM22 deficiency lead to actin cytoskeleton collapse[23]. This cytoskeleton collapse probably
induced inflammation and inflammation dependent ER stress.
Dephosphorylation of eukaryotic translation initiation factor 2a (eIF2a) restores protein synthesis
at the end of the adaptive UPR. It requires a PP1 catalytic subunit and a regulatory subunit,
PPP1R15A(GADD34)/ G actin[109].Sm22α deficiency is also known to increase the Gactin/Factin
ratio[23]. Increased availability of G actin allows the complex formation of GADD34, PP1 and actin
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which dephosphorylates elF2alpha. This helps resume the protein synthesis following its inhibition. It is
suggested that this might be a pro survival response during transient ER stress but may prove fatal during
chronic ER stress[110].We show that cytochalasin D treatment alone is sufficient to induce ER stress.
This can be explained by the fact that cytochalasin D depolymerizes actin by competitive binding to the
barbed ends. This creates a pool of the G actin and association with the GADD34 [111]. eIF2α is
dephosphorylated leading to unresolved protein accumulation and probably a switch to apoptotic UPR
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Figure 19: Actin depolymerization with cytochalasin D induces ER stress and upregulation of
Fbn1 expression. Thapsigargin treatment along with cytochalasin D induces higher ER stress
and blocks upregulation of Fbn1. A) qPCR assay showed Chop and Atf4 gene upregulation with
cytochalasin D treatment alone and higher expression when treated with thapsigargin and cytochalasin
D compared to thapsigargin treatment alone. B) Actin depolymerization causes an increase in Fbn1
expression probably as a compensation mechanism. This upregulation is blocked under ER stress
conditions. N= 3-6. P value *, ** and *** indicate p<0.05, p<0.01 and p<0.001 respectively vs the
control(cntrl).
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VI. Drug screen for natural compounds that can positively regulate Sm22 expression
1. Background:
As SM22 overexpression showed some reduction in ER stress response and ER stress induced
inflammation, hence we screened for natural compounds that could increase SM22 expression. The
potential of SM22 as a therapeutic target is also strenghtened by the fact that SM22 expression is
downregulated in a number of cancers too.The screen for the compounds was carried out at our
collaborator- Andrew Fribley’s robotic screen core facility. A repoter cell line using CHO cells
transfected with Sm22 promoter-luciferase was constructed.CHO cells do not express any SM22
endogenously.The candidate compounds from the screen were then validated in our mouse fibroblast cell
line 10T1/2, a progenitor for SMCs.
2. Results:
We found a group of compounds called isoflavenoids which were able to induce Sm22 expression
(Fig.20). We then verified those compounds in our fibroblast cell line. The fibroblasts were used for the
reporter as they endogenously express low levels of SM22 unlike the SMCs which express very high
levels of SM22.This helps detect any small increase in SM22 expression during the drug screen. The cells
in the preliminary screen wre treaed with the drug for 16-48 hrs. but the same treatment time in the
fibroblast cells did not yield the same result. Subsequent efforts at earlier time points revealed significant
and robust increases of Sm22 between 1–6 hours. The proteins levels were found to be upregulated at the
same treatment time as the screen (Fig.21)
3. Discussion:
Isoflavones belong to a group of phytoestrogens.Isoflavones are commonly found in soy and red
clover. Phyestrogens have been shown to have a cardioprotective effect. Two phytoestrogens biochanin A
and formononetin have been shown to inhibit pdgf induced migration in aortic smooth muscle cells.
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These among the top hits in our drug screen. We chose to do further analsysis with biochanin A as it was
shown to be more potent than other phytoestrogens from our list in some instances[112].
Biochanin A(BCA) is an O-methylated isoflavone. Its found in red clover, soy, alfalfa
sprouts,peanuts and in legumes.Biochanin A has been shown to attenuate LPS induced NF-kB activation
and dependent expression of VCAM-1 and ICAM-1by activating PPAR-γ[113, 114].
We are proposing that its anti-inflammatory effects could be through the increased expression of
SM22. The isoflavones have been shown to inhibit the cytochrome P450[115, 116]. The cytochrome
P450 are a superfamily of hemoproteins. They are either located in the inner membrane of the
mitochondria or the ER. The enzyme is responsible for metabolising a wide range of endogenous or
exogenous chemicals and drugs.There are 18 families of CYP genes. Biochanin A has been shown to
reduce the activity of Cyp2e1 in Ccl4 treatment[117]. This is of significance as , Cyp2e1 gene was found
to be upregulated in Sm22α-/- mice[118].Hence the isoflavone’s therapeutic properties might be SM22
dependent and further analysis could lend more significance to SM22’s role in cardiovascular pathologies.
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Figure 20: Flavones and isoflavones were the top hits in the drug screen for Sm22 expression
inducing agents. 75 hits were parsed to identify compounds amenable to use in cell culture and
preclinical small animal models, with a preference for known utility for use in humans. Eleven
flavone compounds were chosen for confirmatory secondary assays based on structural similarity and
broad reported use in pre-clinical and clinical human studies. Flavones and isoflavones belong to the
class of phytoestrogen and have effects on CYP450 activity. CYP450 are the enzymes that metabolize
most of the drugs in the body. Phytoestrogens have been shown to have cardioprotective effect and
commonly found in soy and red clover. Biochanin A and formononetin have been shown to have antiinflammatory effects.
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Figure 21: Biochanin A upregulated Sm22 expression in the fibroblast cell line 10T1/2. The
phytoestrogen biochanin A (BCA) was chosen for further scrutiny with experiments focused to
validate the ability of the primary CHO-SM22-luc HTS assay to identify hits able to modulate SM22
gene and protein expression. (A)10T1/2 cells were treated with 0.5 or 1.0 uM BCA for 16 – 48 hours
(same as the HTS) without significant increase in Sm22 gene expression. Subsequent efforts at
earlier time points revealed significant and robust increases of Sm22 between 1–6 hours. (B)Western
immunoblot analysis during the same time frame demonstrated that BCA could induce SM22 in a
time- and dose-dependent fashion. N= 3-6. P value ** and *** indicate p<0.01 and p<0.001
respectively vs the control(cntrl).
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CHAPTER 3 -MATERIALS AND METHODS
3.1 Tissue culture
Rat pulmonary smooth muscle cell line PAC1 was used for all experiments except for the drug
screen. For the drug screen validation mouse fibroblast cell line 10T1/2 ( ATCC C3H/10T1/2,clone
8,CCL-226) was used.The cells were grown and maintained in DMEM (Invitrogen,11995073)
supplemented with 10% Fetal bovine serum (FBS,Invitrogen, 26140079) , antibiotics pencillin and
streptomycin (P/S,Invitrogen 15070063) and fungicide ( Invitrogen, 15290026) were used at a final
concentration of 1%.The cells in general were grown for 24-48 hrs before any drug treament.PBS
(#10010049) and Trysin (#25200072) were ordered from Invitrogen.For transfections ,serum free
medium,opti-MEM (Invitrogen # 31985062) was used.
Cell passaging and freezing – Cells in T75 flask were washed with PBS. 1ml trypsin is added and
put in the 37C cell culture incubutor for 3mins. The trypsin is inactivated by adding medium. The cells
are then split into new flasks.For freezing,the cells are centrifuged and the supernatant discared. Cells
from a T75 flask are resuspended in 2-3 ml of cell recovery freezing medium(Fisher # 12-648-010 )and
aliquoted into labelled freezing tubes and placed in the cell freezing box at -80C. To thaw, the cells are
placed in a 37C water bath for 1 min and then warmed medium is added to the vial. The cells are then put
in the cell culture flask and allowed to attach overnight.
3.2 Genotyping and Aorta isolation
C57BL/6 mice were used for the Sm22 knockout colony.The Sm22 gene is knocked out using
LACZ insertion.Mouse toe tissue was used to genotype the mice. The tissue was digested overnight in
100ul of digestion buffer( Viagen,#102-T) with 4ul (20mg/ml) of proteinase k ( 501-PK) at 37C. The
proteinase K is inactivated by heating the sample on a heating block at 95C for 15 mins.The DNA sample
is stored at -20C. For genotyping, a reaction mix for a single sample is made using 10ul of red master
mix (ASI # C225), 1ul DMSO, 0.4ul of forward primer, 0.4ul of reverse primer and 8.2 ul of water.To
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this 2.5 ul of digested DNA is added.The primer sequences for genotyping are mentioned in the table
1.The PCR conditions sre as follows: for Sm22: 94C – 3:00 mins, 94C – 0:30 min, 52C- 0:30, 72C- 0:40,
39 cycles and then 72C for 10:00 mins. LacZ: 94C – 3:00 mins, 94C – 0:30 min, 58C- 0:30, 72C- 1:00, 39
cycles and then 72C for 10:00 mins.
Table 1 : Primer sequences used for genotyping
SM22 forward

CCCAGCCCAGACACCGAAGCTAC

SM22 reverse

TCCCTTGGCCTCATTTGTCACCTC

LacZ forward

TACCACAGCGGATGGTTCGG

LacZ reverse

GTGGTGGTTATGCCGATCGC

3.3 Protein isolation
The protein from cells was isolated using the reagent M-PER from (Thermofisher#78501).The
cells are washed twice with PBS and then M-Per reagent was added. Protease (Thermofisher#78429) and
phosphatase inhibitors(Fisher, #PI78443) were added to the M-Per reagent at 1:100 dilution.The cells are
incubated on ice on a rotor for 5 mins. The cells were then scraped and the lysate collected.The lysate was
then incubated in ice while shaking for 20-40 mins.The lysate was then centrifuges at ~14000g for
10mins.The supernatant was transferred to a new tube and stored at -20C.
3.4 Protein quantification
The protein quantification was done using the Quant-iT™ protein quantification kit
(Fisher#Q33212) and qubit benchtop fluorometer from Fisher# Q32857.The pre-diluted BSA standards
provided in the kit were used. A working solution is prepared by diluting (1:200) the Quant-iT reagent in
Quant-iT buffer provided in the kit.1 ul of protein sample is added to 199ul of working solution , vortexed
and incubated for 15 mins. 10ul of standards us added to 190ul of working solution.Readings are taken in
the fluorometer.
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3.5Western blot
Equal amount of whole cell lysates from PAC1 cell or 10T1/2 samples were loaded on a 4-12%
Bis-Tris NuPAGE Mini-gel (Invitrogen# NP0321) for electrophoresis, followed by transfer onto an
Immobilon-P membrane (Millipore # IPVH00010). The running (# NP0001) and transfer buffer (#NP
00061) from Invitrogen was used. The buffers were used at a dilution of 1x. The membrane was blocked
with 5% milk (Fisher# NC9121673) in TBST for 1 Hr., followed by primary antibody (diluted in milk)
incubation overnight at 4 °C. The membrane is washed 3 times in TBST for 5 mins and then incubated
with biotinylated secondary antibody for 2 Hrs. The membrane is washed in TBST again 3 times for 5
mins. The membrane was subject to enhanced chemiluminescence detection using Super Signal West
Pico Chemiluminescent Substrate (Thermo # 34080). The primary antibodies used are listed in the Table
2.
Table 2. Antibodies used for Western

Gene

Company

Catalog No.

Dilution

Sm22

Abcam

ab14106, ab10135

1:1500

Sma

abcam

7817

1:2000

Klf4

Sigma

HPA002926

1:250

Atf4

Santa Cruz

Sc-200

1:200

Chop

Santa Cruz

Sc-7351(WB),

1:200

sc-793(IHC)
Β actin

Cell signaling technology

4967S

1:1500

Southern biotech

1070-05(for sc 7351)

1:2000

Santa cruz

Sc 2962

Secondary
ab
Anti-mouse
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Anti-goat

Santa cruz

Sc 2961

1:2000

Anti-rabbit

Santa cruz, sigma

Sc 2955, SAB3700941

1:2000

3.6 RNA isolation
RNA isolation for the cells was carried out using the Direct-zol RNA Miniprep kit from Zymo
research(#R2073). The cells were treated with trizol and buffers from the kit are used to carry out the
subsequent steps. For cells grown in a 6 well plate 800ul of trizol was added and incubated for 5 mins.
The trizol was collected and added to DNase/RNase free tubes with 800ul of 100% ethanol and mixed
well. The solution was then added to the columns provided in the kit. The columns were centrifuged at
16000g for 30sec (for all steps except where mentioned). The columns were then washed with 400ul of
RNA wash buffer and centrifuged. The column was then treated with DNase I (75ul of digestion buffer +
5ul of DNase I) and incubated at room temperature for 15 mins.400ul of directzol buffer was then added
to the column and centrifuged and this step was repeated. 700ul of RNA wash buffer was then added to
the column and centrifuged for 2 mins.50 ul of DNase/RNase free water was added directly to the column
to elute the RNA. The RNA concentration was determined using the nanodrop ND-1000
spectrophotometer and stored at -80C. A sample was considered pure enough for experiments if the
absorbances at 260/280 and 260/230 ratio were at least 1.8 and 1, respectively.
For ex vivo organ culture, the tissue was homogenized using a homogenizer. The tissue was
either used fresh or stored in RNA later solution (Ambion# AM7021) and RNA isolation was carried out
at a later time point.
3.7 cDNA preparation
500ng -1000ng of RNA was used to make the cDNA. The cDNA was synthesized using the
Superscript II reverse transcriptase (18064014), Random primers (48190011) and buffers from
Invitrogen.2ul(3ug/ul) of random primer and 2ul of dNTP mix (10mM each, Invitrogen #18427013) was
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added to 500-1000ng of RNA and volume made up to 23ul with distilled water. The mixture was heated
to 65C for 5 mins and quick chilled in ice. The contents were briefly centrifuged. 8 ul of 5x buffer and 4ul
of 0.1M DTT was added. The contents were mixed gently and incubated at room temperature for 2 mins.
200U of superscript was added. It was incubated at 25C for 10 mins. The mixture was then heated at 42C
for 50mins. The reaction was inactivated by heating at 70C for 15mins.
3.8 Quantitative PCR
Real-time PCR was performed using SYBR Green (Invitrogen # 4385616) on a StepOne Plus
system (Applied Biosystems). Gapdh and snRNA U6 were used as internal controls in ΔΔCt method. The
primers were ordered from IDT. The sequences for the primers for mouse and rat are listed in Table 2.A
total of 10 ul reaction mixture is added to each well.5ul of SYBR and 4ul of primer(2.5uM). To this 1ul of
cDNA made from 500-1000ng of RNA is used. The reaction run had 3 stages- Holding stage- 95C for
20sec, cycling stage- 95C for 3 sec, 60C for 30 sec repeated 40 times and Melt curve stage – 95C for
15sec and 60C for 1 min.
Table 3 Primer sequences for RT-PCR
Gene

Forward (5’-3’)

Reverse (5’-3’)

RAT
Sm22

TCCTTCCAGCCCACAAACGACCAA

CTTGGACTGCACTTCACGGCTCAT

Acta 2

GAGAAGCCCAGCCAGTCG

ATCTTTTCCATGTCGTCCCAGTTG

Cnn1

GCGTCACCTCTATGATCCCAAACT

GTTGAGCGTGTCACAGTGTTCCAT

Myocd

CAGTGAAGCAGCAAATGACTCGG

GTCGTTGGCGTAGTGATCGAAGG

Flna A

ACTGTTTCTAGCCTTCAGGAG

GCACAGCATACTTATCTTGGTC

Vim

CGGAAAGTGGAATCCTTGCA

CACATCGATCTGGACATGCTGT

Tubb

GCAGTGCGGCAACCAGAT

AGTGGGATCAATGCCATGCT
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Tagln 2

ATTGAGAAGCAGTACGACCCAGAT

AGAGGCCTGGATCTTCTTTACTGG

Myh11

AACGCCCTCAAGAGCAAACTCAGA

TCCCGAGCGTCCATTTCTTCTTCA

Atf4

GGGTTCTGTCTTCCACTCCA

AAGCAGCAGAGTCAGGCTTTC

Chop

CCTAGCTTGGCTGACAGAGG

CTGCTCCTTCTCCTTCATGC

Klf4

AGGCACACCTGCGAACTCA

ACAGCCGTCCCAGTCACAGT

Pdgf-bb

CGCACAGAGGTGTTCCAGATC

CCAGGAAGTTGGCGTTGGT

Mmp9

TCTTCGACTCCAGTAGACAATCCT

ACTTCCAATACCGACCGTCCTTGA

Grp78(Bip) TCCTGCGTCGGTGTATTC

CGTGAGTTGGTTCTTGGC

Calr

GAATACAAGGGCGAGTGGAA

GGGGGAGTATTCAGGGTTGT

Runx2

CAGGTTCAACGATCTGAGATTTGT

TGAAGACCGTTATGGTCAAAGTGA

Msx2

GCCATTTTCAGCTTTTCCAG

CCCTGAGGAAACACAAGACC

Ocn

AAGCCCAGCGACTCTGAGTCT

GCTCCAAGTCCATTGTTGAGGTA

Pit-1

CCGTCAGCAACCAGATCAACTC

CCCATGCAGTCTCCCACCTTG

Vcam-1

TGTGAAGGGATTAACGAGGCTGGA

GCACACTTCCACAAGTACAGGAGA

Ccl2

CAGTTAATGCCCCACTCAC

GTTTCTGATCTCACTTGGTTCT

TCCTTCCAGTCCACAAACGACCAA

TTTGGACTGCACTTCTCGGCTCAT

Gapdh

TGAATACGGCTACAGCAACAGGGT

TTGTGAGGGAGATGCTCAGTGTTG

U6

CTCGCTTCGGCAGCACATATACTA

CGCTTCACGAATTTGCGTGTCATC

Mouse
Sm22
Same

for

mouse and
rat
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3.9 Immunoflorecence
PAC1 cells attached to chamber slides were rinsed twice with PBS and liquid removed by gentle
aspiration. The control and treatment groups are on the same slide. The cells were then fixed in -20C
methanol for 5 mins. The cells were washed with PBS 3 times for 5 mins. The cells were then blocked
and permeabilized using the blocking solution (1ml chicken serum, 20ul of Triton X-100(Fisher #BP151500) and 9ml PBS, vortexed until dissolved) for 1 hr. at 37C.The primary antibody was diluted in 5%
serum at a dilution of 1: 100.The cells were then incubated 1-2 hrs. at 37C in a moist chamber to prevent
drying. The cells were then washed 3 times in PBS for 5 mins, then 2 times with 10% serum. The cells
were then incubated with secondary ab diluted in 5%serum at a dilution of 1:200 for 1hr at 37C in the
moist chamber. The cells are then washed 3 times with PBS for 5 mins. Cover slips were mounted with
Vectashield with DAPI (Vector labs# H-1200). The images were captured using the Nikon Eclipse Ti inverted microscope.
3.10 Immunohistochemistry
The slides with OCT (VWR, #102094-106) sections was first air dried for 5 mins. The sections
were fixed in pre-chilled methanol containing 0.3%H2O2 for 10 minutes at -20 °C. Its then washed in PBS
for 5 mins. The sections are incubated for 20 minutes with diluted normal blocking serum which was
prepared from the species in which the secondary antibody is made. Blot the excess serum from the
section. sections are incubated for 30 minutes with primary antiserum diluted in PBS. The slides are then
washed in PBS for 5 mins. The sections are then incubated with biotinylated secondary antibody for 30
mins. The slide is then washed in PBS for 5 mins. The slide is the incubated for 30 minutes with
VECTASTAIN® ABC Reagent (Vector labs, PK-6100). The reagent is made and let to stand for 30 mins
before use. The slides are then washed in PBS for 5 mins. The sections are then incubated in peroxidase
substrate for until desired intensity is achieved (The substrate solution should be made just before use).
slides are then immersed in tap water for 2 minutes to get rid of PBS residue, otherwise you may get high
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pink background after hematoxylin counterstaining. Its counterstained with Gill’s formula hematoxylin
for 10 to 20 seconds. slides are then immersed in bluing solution for 1 minute (Bluing solution: 1.5 ml
NH4OH (30% stock) + 98.5 ml of 70% ethanol), then rinsed in tap water. Immerse into 100% ethanol for
5 minutes and airdry. Then in xylene for 6 mins and air dry. The coverslip is mounted using permount
mounting medium. Both positive and negative controls are one single slide.
3.11 TUNEL assay
The TUNEL assay was performed using the DeadEnd colorimetric TUNEL system from Promega
(# G7130). Both the control and test sample sections are located on the same slide. The slide is immersed
in 0.85% NaCl for 5 mins at room temperature. The slide is then washed in PBS for 5 mins at RT. The
sections are then fixed in 4% paraformaldehyde for 15 mins at RT. The slides are immersed in PBS for 5
mins and repeated.100ul of 20ug/ml proteinase K is added to the tissue sections and incubated for 30
mins at RT. The slide is washed in PBS for 5 mins at RT. The slide is re-fixed and immersed in PBS for 5
mins. The sections are then incubated in the equilibration buffer for 10 mins at RT. The biotinylated
nucleotide mix is thawed on ice and the rTdT reaction mixture is prepared. Each section was covered in
100ul of reaction mixture (98ul equilibration buffer+ 1ul nucleotide mix+1ul rTdT). For negative
controls, the rTdT is replaced by deionized water. The slides are incubated in a humidified chamber at
37C for 1hr.The reaction is terminated by immersing it in 2x SSC for 15 mins at RT. The slide is washed
in PBS for 5 mins,3 times to remove unincorporated biotinylated nucleotides. Endogenous peroxidases
are blocked by immersing the slide in 0.3% hydrogen peroxidase solution. It is washed in PBS for 5mins
3 times. The streptavidin solution is diluted in PBS 1:500 and 100ul is added to each section. The slide is
incubated for 30mins.the slide is then washed in PBS for 5 mins ,3 times each. The DAB solution should
be prepared just before use and kept away from light.50ul of DAB buffer is added to 950ul of ionized
water.50ul of chromogen and 50ul of hydrogen peroxidase is then added to the buffer solution.100ul of
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this solution is added to each section. The sections are incubated until the desired intensity is achieved.
The slide is rinsed in water several times and cover slip is mounted.
3.12 Adenovirus Transfection
Adenovirus was grown in HEK 293 T cells and harvested. The cells were grown in 10cm dishes
and let to reach a confluency of 80%. Once the cells had reached the desired confluency, they were
infected with the virus. The virus positive cells were positive for GFP. The cells were monitored and
expanded when enough GFP signal was detected(~48 hrs).The virus was expanded in a similar manner to
5 – 10cm dishes.For harvesting, the cells were collected in a 50ml conical tube.They were pelleted at
1000rpm for 10mins.The supernantant was discarded.The cells were rinsed in PBS and pelleted at
1000rpm for 10mins. The cells were resuspended in 10mM Tris, pH 8.1(1ml for each 10cm dish).The
cells were then lysed in ice/water bath at 37C. This step was repeated a total of 3 times.It was then
centrifuges at 12000rpm for 10 mins.The supernatant is discarded. The virus is stored at -70C.The virus
was then used to infect PAC1 cells. Once the cells gave desired GFP signal, the cells were treated with
Thapsigargin and RNA isolated.
3.13 Plasmid transfection for MYOCD overexpression
PAC1 cells were grown in 6 wells plates. Cells were plated at a conc. of 10x104 cells/well. They
were transfected once they reached 80% confluency. Lipofectamine and Plus reagents (Invitrogen) were
used.1 ug of plasmid DNA was used to transfect cells in each well of the 6 well plate. Plasmid DNA was
diluted in 210 ul of Opti-mem and 6.3 ul of plus reagent. It is necessary to dilute DNA in medium before
the reagent to avoid DNA precipitation. In a second tube 4.2ul of lipofectamine is added to 210 ul of
media. The tubes are incubated for 15 mins at room temperature. The contents of the two tubes are mixed
and incubated for an additional 30mins at room temperature. During the incubation, the cells medium is
removed and washed with serum free medium and 1ml of Opti-mem is added to the cells. The
transfection mix is then added to the wells and put at 37C in the incubator. After 3 hrs. the medium is
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changed to normal medium (10% FBS). RNA was harvested 72hrs after transfection. Thapsigargin (1uM)
was added to the treatment wells 24 hrs. before RNA isolation.
3.14 Plasmid transfection for Luciferase assay
PAC1 cells were grown in 96 well plates. The cells were plated at a conc. of 7.5x103/well. They
were transfected once they reached 80% confluency. Lipofectamine and Plus reagents (Invitrogen) were
used. For the renilla luciferase pRL-CMV vector from Promega (Cat# 2261) was used as internal control.
The different promoter mutations are detailed in the publication from our previous lab member[100].In
tube one, to 10ul of media 1ul of plasmid(50ng/ul), 1ul of renilla plasmid(1ng/ul) and 1ul of plus reagent
is added. In tube two, 10ul of media and 0.5ul of lipofectamine is added. After an initial incubation of 15
mins at RT, the contents of the two tubes are mixed and incubated for an additional 15 mins. The reaction
mixture of total 24.5ul is added to each well. After 3 hrs. of incubation another 125.5ul of normal 10%
FBS medium is added to the wells. Thapsigargin (1uM) was added to the treatment wells 24 Hrs. before
the assay.
3.15 Luciferase assay
The dual luciferase reporter assay system from Promega (Cat# E 1960) was used. All reagents are
thawed at room temperature for at least 1 hr. 5x passive lysis buffer was diluted to 1x using distilled
water. Once the cells in 96 well plates are ready after transfection, the cells are washed with PBS and 22ul
of passive lysis buffer was added to each well. The plate was put on a shaker for 15 mins. 20ul of the
lysate is transferred to a white 96 well plate to be read in the luminometer. In this assay the activities of
firefly (Photinus pyralis) and Renilla (Renilla reniformis or sea pansy) luciferases are measured
sequentially from a single sample. The firefly luciferase reporter is measured first by adding Luciferase
Assay Reagent II (LAR II) to generate a luminescent signal. After quantifying the firefly luminescence,
this reaction is quenched, and the Renilla luciferase reaction is initiated simultaneously by adding Stop &
Glo® Reagent to the same sample. The firefly luciferase value was normalized using the renilla luciferase
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value. The lyophilized luciferase assay substrate was resuspended in 10ml of luciferase assay buffer II.
The 50x stop and glo substrate was diluted to 1x using the stop and glo buffer. Both the final reagents
were used to prime the tubing of the luminometer before the sample was read. Veritas 96 well
luminometer was used to read the plate.
3.16 Chemicals
Thapsigargin (Sigma # T9033) was diluted in DMSO and 10uM stock solution was prepared.
Thapsigargin was used at a conc. of 1uM. Cytochalasin D (Sigma # C8273-1mg) was dissolved in DMSO
and used at a final conc. of 1uM. Palmitate solution was made by conjugating it with BSA. Palmitic acid
(#P0500-10g) and BSA(#A8806-1g) was ordered from Sigma. BSA was dissolved in DMEM to give
10%FFA BSA. Palmitic acid was dissolved in ethanol to make 200mM stock solution. 40ul of palmitate
and 1960ul of 10%FFA-BSA was mixed to make a 4mM stock and incubated overnight at 37C to
conjugate.
3.17 High Throughput Screening (Performed by Dr. Andrew Fribley’s lab)
Cell lines and reporters- CHO-K1 cells (ATCC, Manassas, VA) were grown in F-12 medium with
glutamax (# 31765-035, Life Technologies, Carlsbad, CA), supplemented with penicillin and
streptomycin in a standard tissue culture incubator at 37 °C with 5% CO2. A pool of cells was transfected
with pSM445GL4.21luc2P-puro (SM22-luc) and selected with 1.0mg/ml of puromycin for ten days. For
screening, a single high-expressing clone that provided Z’ values = 0.7 was identified from the pool.
Screening - 5000 CHO-SM22-luc reporter cells were plated onto white 96-well tissue culture plates and
incubated for 16 hours (overnight) at 37 °C, 5% CO2, prior to compound addition. Compounds from the
MicroSource Spectrum Collection, containing ~2400 biologically well-characterized small molecules and
natural products including many FDA-approved drugs dissolved at 10mM in DMSO, were added using a
high-density replication (HDR) tool on a Biomek FX liquid handler (Beckman Coulter, Brea, CA) in a
0.05ul volume (DMSO concentration = 0.1% in all wells). All compounds were tested as singletons at
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final concentration of 10mM. 0.3 uM panobinostat (Pano) or an equal volume of DMSO was each added
to one row of wells on each plate for assay controls. Sixteen hours later the medium was aspirated to 25 ul
and 25 ul of Bright-Glo (E2620, PromegaCorp, Madison, WI) was added to each well and allowed to
come to equilibrium at room temperature for 10 minutes. Luminescence was measured on a Flexstation 3
multi-mode plate reader (Molecular Devices, Sunnyvale, CA). A hit was defined as a compound able to
induce luciferase to a level ≥120% of the panobinostat control.
3.18 Statistical analysis
Data analysis was carried out in the software GraphPad Prism. Graphs show mean with SEM.
Where appropriate t-tests or one-way ANOVA with Tukey's or Dunnett's post hoc tests were performed.
Results were considered statistically significant when p<0.05. Statistical significance is indicated with
asterisks: * denotes p between 0.05 and 0.01, ** denotes p between 0.01 and 0.001, *** denotes p<0.001.
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DISCUSSION
Most of the stress signaling mechanisms in the cell are meant to restore homeostasis by diverting
resources to the injured or stressed area. In many cases though, the signaling due to several reasons might
become deleterious and the cells need to switch to a damage control mode. The smooth muscle cells
inhabiting the vessel wall undergo wear and tear due to mechanical stress and various environmental
stimuli. As a result, various signaling pathways are activated such as inflammation, oxidative stress and
cyclic strain signaling. When the cells become overwhelmed and need to stop further damage, they signal
for apoptosis. Apoptosis when unchecked can lead to loss of tissue viability and irreversible functional
damage. Hence it is necessary to understand the triggers and factors leading to apoptosis under various
stress mechanisms. Among the various stress responses in the VSMCs, ER stress seems to be one of the
lesser studied mechanisms. Its activation in a wide range of cardiovascular diseases, warrants the need for
further analysis.
Presence of ER stress (ATF 4 and CHOP) and apoptosis was established in our mouse model of
genetic stress induced aortic aneurysm. Sm22 deletion was made in the Marfan (MFS) mouse to generate
a Fbn1C1039G/+: Sm22-/- mouse model. SM22 deficiency has been shown to cause decreased vascular
contractility but otherwise have a normal development. SM22 deficiency by itself does not have any
significant impact on aneurysm formation. Excessive TGFβ signaling has been shown to contribute to
aneurysm formation in MFS mice. Deletion of Sm22 in the Marfan mice exacerbated the aneurysm
formation. Apoptosis of smooth muscle cells is thought to be the primary reason for smooth muscle cell
loss in aneurysm[73, 74].Consistent with these studies we show presence of ER stress induced apoptosis
in our mouse model. This also points to the association of ER stress with aortic aneurysm irrespective of
the etiology. The results also highlight a potential protective role of Sm22α under stress. It suggests that
under quiescent conditions Sm22α might be compensated but it may play an active role in stress
conditions.
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The PERK arm of the ER stress signaling is thought to be the apoptotic arm of the stress process.
PERK-dependent phosphorylation of eIF2α enhances ATF4 protein levels during ER stress. ATF4 is
known to induce the pro-apoptotic factor CHOP. Microarray studies have shown that CHOP is the highest
inducible gene during ER stress. CHOP protein undergoes phosphorylation at Ser78 and Ser81 by p38
MAP kinase family. Phosphorylation enhances transcriptional activation and elicits a maximal apoptotic
effect of CHOP[119]. Deletion mutant analysis of CHOP revealed that bZIP domain is important for
CHOP-induced apoptosis[120, 121].
The effect of ER stress induced signaling in smooth muscle cells was studied. The smooth muscle
cell line PAC1 was treated with a pharmaceutical ER stress inducer thapsigargin. Thapsigargin has been
established to induce ER stress dependent apoptosis. Thapsigargin induces ER stress by inhibiting
SERCA and causing ER store depletion of calcium. SM22α is an actin binding cytoskeletal
protein.SM22α and SMA are characteristic markers for smooth muscle phenotype. The cytoskeletal
proteins work in tandem with the extracellular proteins to maintain the mechanical and functional
integrity of the vessel wall. The expression of several cytoskeletal, smooth muscle and ECM genes with
thapsigargin treatment was observed. At 24 hrs. treatment point significant apoptosis was observed.
Hence 24hrs was chosen as the maximum treatment time. All the smooth muscle, cytoskeletal and ECM
genes observed were found to be downregulated at the 24 hrs. treatment time. A time course analysis of
Sm22 and Sma showed a transient upregulation at 1-6 hrs. treatment time before downregulation. This
increase in the expression could be a compensatory mechanism of the adaptive phase of the ER stress.
Studies have shown that the ER depends on the actin cytoskeleton for their morphology and functions like
ER-Golgi trafficking[122]. These aspects of the ER play a vital role in the ER-UPR.
Thapsigargin treatment also results in upregulation of ER stress chaperones calreticulin and
Grp78(Bip). Calreticulin (CRT) is shown to mediate ECM production by TGFβ in fibrotic
conditions[123]. As mentioned before excessive TGFβ signaling is present in aneurysm of Marfan mouse.
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ER stress induced CRT might contribute to excessive amounts of ECM deposition, a characteristic of
synthetic phenotype of VSMCs.
The ER stress also induced transcription factors like Klf4, Pdgfbb and metalloproteinase like
Mmp9. These markers contribute to the switch from contractile VSMCs to the synthetic phenotype. The
VSMCs in the synthetic state secrete increased amounts of extracellular matrix components to repair the
vessel wall integrity. Another hallmark of the synthetic state is loss of contractile markers. The
phenotypic modulation though in most cases proceeds to apoptosis. The apoptosis of the smooth muscle
cells leads to loss of cells in the vessel tissue which leaves it more prone to damage. The phenotypic
marker Pdgf-bb is known to induce expression of Klf4 through Sp1 binding to the Klf4 promoter[124].
Traditionally, Klf4 is known to repress the transcription of smooth muscle markers. KLF4 is known to
repress the expression of smooth muscle markers through several mechanisms. KLF4 binds the CArG box
in the Sm22 promoter replacing the Sm22 inducing SRF-MYOCD complex. It also recruits HDAC2 to
block the SRF complex from binding the promoter. KLF4 also represses the expression of smooth muscle
master regulator MYOCD. Recent studies however show that the post translational modification of Klf4
determines its function as enhancer or repressor. The non SUMOylated Klf4 is known to induce the
expression of smooth muscle genes whereas the SUMOylated form represses the SM gene
expression[125]. This is probably why we see an increase in the smooth muscle genes accompanied by
increase in Klf4 expression
We checked for parallel signaling mechanism that were induced due to ER stress and ones that
could also induce phenotypic modulation. We found that the inflammation markers Vcam-1 and Ccl2
were upregulated. Vcam-1 is a cell adhesion molecule. Cell adhesion molecules are transmembrane
glycoproteins that mediate cell-cell and cell-extracellular matrix interactions. Ccl-2 is a chemokine.
Chemokines are a superfamily of secreted proteins involved in inflammation and immunoregulation. In
cardiac cell Ccl-2 manifests a protective effect by induction of ER stress chaperones. Prolonged exposure
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to CCL-2 breaks down the protection and results in heart failure[126, 127]. Hence a pre-existing
inflammation may trigger ER stress as a repair mechanism but may turn pathogenic. The inflammation ER stress loop results in extreme response mechanism and ultimately apoptosis. Along with inflammatory
markers, osteogenic markers were also found to be upregulated. The various osteogenic markers were
Runx2, Msx 2, Ocn and Pit-1. Runx2 is a transcription factor whose targets include Ocn. Msx2 is also a
transcription factor contributing to the vascular calcification. Runx2 and Msx2 regulate expression of
many ECM genes. Pit-1 is a sodium dependent phosphate transporter whose expression along with Runx2
and Ocn is mediated by the ER stress induced transcription factor Atf4. Spliced XBP1 is also known to
mediate Runx2 expression[128]
As discussed earlier all these inflammatory and osteogenic markers contribute directly or
indirectly to the repression of the contractile markers. Mutational analysis of the Sm22 promoter
confirmed that many of the cis acting elements in its promoter are involved in its downregulation under
ER stress. We hypothesized that the downregulation of SM22 contributed to more severe inflammation
and ER stress as part of the loop mechanism. This was based on published data from our previous lab
members[22] and confirmed by independent studies[105]. These studies showed SM22 deficiency caused
inflammation and oxidative stress. We overexpressed SM22 by adenovirus under the ER stress condition
and found that it could reduce the expression ER stress and inflammation markers.
Myocardin is known to be the master regulator of smooth muscle genes and myocardin itself is
downregulated under ER stress. We overexpressed myocardin to see if it would rescue the SM22
downregulation and dependent pathogenic signaling. Myocardin reduced the downregulation of SM22 in
all the promoter mutants. Myocardin overexpression reduced Vcam-1 expression but not Ccl-2 or the ER
stress markers.
Another aspect of the regulation of contractile markers is the cytoskeletal dynamics. Apart from
the gene expression, the state of the contractile protein also plays a key role in the signaling process.
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Sm22 deficiency can collapse the actin cytoskeleton and induce oxidative stress. We used an actin
depolymerizer cytochalasin D to treat the cells. We found that depolymerizing the actin cytoskeleton was
sufficient to induce ER stress. The oxidative stress induced due to the actin cytoskeleton collapse could be
the trigger for inducing ER stress. Adding the depolymerizers along with thapsigargin leads to a higher
stress response. Another contributing factor is the availability of G-actin. G actin can bind to factors like
PP1/GADD34 complex to dephosphorylate elF2α and resume global protein translation prematurely. This
leads to termination of the adaptive phase of the response before the problem has been resolved causing
higher stress.
We show that SM22 plays a protective role in the ER stress process and upregulating its
expression might help downregulate other pathogenic signaling like inflammation and osteogenesis. A
drug screen was therefore carried out to identify compounds that could increase Sm22 expression. The
compounds that scored the highest in the drug screen belonged to the group of phytoestrogens called
isoflavonoids and its metabolites. This class of compounds is known to repress the expression of
cytochrome P450.Sm22 deficiency is also known to increase cytochrome P450 expression. Hence it could
be a potential mechanism through which flavonoids increase Sm22 mechanism. Biochanin A, a
phytoestrogen was chosen to validate the result in the fibroblast cell line, a SMC precursor. Biochanin A
upregulated Sm22 expression at gene and protein level. The screen is strengthened by studies that show
the anti-inflammatory role of biochanin A against LPS induced inflammation[113]. Hence Sm22 might be
a potential drug target to attenuate the pathogenic effects of ER stress.
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Figure 22: Working model of Sm22 regulation under the ER stress and role of inflammation and
osteogenic pathways activated under ER stress. The ER stress transducers IREα and PERK activate
signaling that leads to repression of Sm22 expression. 1)PERK phosphorylates elF2α which activates a
translational attenuation. This attenuation causes reduced IkBα and SM22 that sequester NF-kB in a
complex. The free NF-kB translocates to the nucleus to repress Sm22 expression and induce
expression of inflammatory markers. The Sm22 repression by NFkB then works in a loop mechanism
to increase translocation of NFkB. 2-3) Downstream to PERK and elF2α is ATF4. ATF4 induces the
expression of RUNX2 and KLF4. RUNX2 represses MYOCD, the master regulator (positive) of Sm22
expression. RUNX2 also displaces the SRF-MYOCD complex form the CArG box leading to reduced
Sm22 expression. RUNX2 also induces the expression of osteogenic markers. XBP1 downstream to
IREα induces RUNX2. KLF4 works in comparable manner by repressing MYOCD and displacing the
SRF-MYOCD complex. ATF4 also induces PIT-1 which represses Sm22 by methylating its promoter.
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CONCLUSION
Cardiovascular diseases (CVDs) are a major health and economic burden globally.It is estimated
that >1 in 3 American adults have CVD. Often a person will have more than 1 type of CVD due to
interdependent complications.Data from 2013 shows that ~2200 people die of CVD every day, averaging
to one every 40 secs [129].It is estimated that if all the forms of CVD are eliminated the life expectancy
could rise by 7 years[130]. It is therefore of utmost importance to find therapies to treat these pathologies.
The CVDs are complicated by a number of secondary signaling processes like inflammation and
vascular calcification. These symptoms are called atherogenic, indicating the development of
atherosclerosis. Aortic aneurysms are often accompanied by inflammation and atherosclerosis. This
subtype is often referred to as the atherosclerotic aneurysm[131].The pathology also differs between TAA
and AAA due their embryonic origin. The SMCs of the AA retain the genetic programming of the
embryonic state whereas the SMCs in the thoracic area are populated by cells that can adapt better to the
rigour and stress of the blood pressure. Hence the cells from these two regions also differ in their response
to different stimuli[132]. Therefore understanding the pathology at the molecular level is vital.
The smooth muscle cells are the predominant cell type involved in these pathologies and hence
the focus is on the unique repertoire of contractile genes that these cells express.The dynamic nature of
the cells in regulating the expression pattern of these genes is a double edged sword.The phenotypic
modulation of the cells under stress results in reduced expression of the contractile markers and increased
expression of inflammatory and osteogenic markers that lead the cells to apoptosis. The ER stress is a
multitier signaling pathway. The two phase ER stress response may be useful to find a time point to
intervene and stop the adaptive UPR from becoming apoptotic. The downregulation of SM22α under ER
stress may not be just a passive outcome. Overexpression of SM22 reduced inflammation and ER stress
markers. It is also regulated by a number of pathways, so there might be more than one path to regulate
SM22 expression, which gives it an advantage as a therapeutic target. Our drug screen identified
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phytoestrogens as positive regulators for Sm22 expression.Given that these candidates are natural
compounds and present in small quantities in the common foods, the chances of toxicity are greatly
reduced. This might be a benfit for the therapeutic development.
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FUTURE DIRECTIONS
Our work shows that the ER stress signaling and the gene regulation of Sm22 is a multitier
complex signaling cascade. We mainly focussed on the gene expression patterns and gene regulation but
the ER stress is regulated at many different levels. Role of miRNAs in the stress response is an emerging
field. miRNAs are small non-coding RNAs that silence RNA and function as post-translational gene
regulation. Several miRNAs have been identified that work as the stress sensors or regulate other
trancriptional factors of ER stress.MiR-211 was shown to be directly induced by PERK[133].MiR-702
was found to regulate ATF6[134]. So studying the regulatory role of miRNAs under the stress response
would open up the doors to deeper signaling pathways.
Another aspect of the project that needs attention is the epigenetic regulation.As dicussed before
KLF4 recruits HDAC2 to block the SRF binding to CArG box. Pit-1 also downregulates Sm22 expression
by methylating the Sm22 promoter. Also the histone acetyltransferase enzyme p300 is recruited to the
Grp78 promoter under ER stress. It then acetylates histone H4 to activate its expression[135].These are
just a few examples.The contribution of epigenetics and chromatin remodelling play a very significant
role in the stress response.
Another layer of regulation that needs to be taken into account is the post translational
modification of different proteins involved in the signaling process.SM22α phosphorylation has been
shown to be the link between actin cytoskeletal remodelling and oxidative stress[136].Though the major
trasnscritption factors like elF2α have been studied , the downstream proteins still need to be explored in
detail.
The newly emerging field though is the exosome biology. Studies have shown that phenotypically
modulated VSMCs show increased secretion of exosomes.These contain miRNA for inflammatory and
osteogenic signals.Exosome biogenesis is not clearly understood in this aspect and might be an important
therapeutic target[137].

62

Figure 23: Diagrammatic representation of future directions for the project- ER stress in
VSMCs.1) Drug screen validation- Only one of the drug screen candidate Biochanin A was validated
in the 10T1/2 fibroblast cell line. Other isoflavones and flavones need to be tested for activation of
Sm22 expression in the fibroblast cells or stresses VSMCs.2) Epigenetic regulation- KLF4 is known to
recruit HDAC2 to the CArG site to displace the SRF-MYOCD complex, repressing the expression of
Sm22.PIT-1 also represses Sm22 expression by methylating its promoter. Hence epigenetic regulation
might be an important regulation pathway.3) Post translational modification of cytoskeletal proteinsAngII has been shown to induce ROS by phosphorylating SM22. How ER stress modifies SM22 post
translationally might be crucial in the stress response.4) Several miRNAs have been implicated in the
regulation of the factors involved in the stress process.5) Recent studies have shown that VSMC
exosomes might play a significant role in calcification of the tissue. Therefore, this novel aspect of
signaling might be a good direction for the project to move forward.6) Effect of physiological ER
stress inducers on smooth muscle phenotypic modulation. Physiological stress inducers might be
clinically relevant to the pathology and hence might be an important aspect of the ER stress project.
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ABBREVIATIONS
10T1/2, mouse fibroblast cell line
ACTA2, smooth muscle α actin;
ATF4, Activating transcription factor 4
ATF6, Activating transcription factor 6;
BCA, Biochanin A;
bp, base pairs;
CArG, CC(A/T)6GG;
CCL2, monocyte chemotactic protein 1;
cDNA, complimentary DNA;
CHO cells, Chinese hamster ovary cells;
CHOP, C/EBP homologous protein;
CNN1, calponin 1;
Cyp2e1, cytochrome P450 2e1
CVD, cardiovascular disease;
CytoD, cytochalasin D;
DAPI, 4',6-diamidino-2-phenylindole;
DMEM, Dulbecco's Modified Eagle's medium;
ECM, extracellular matrix;
elF2α, Eukaryotic Initiation Factor 2 α;
ER, endoplasmic reticulum;
FBS, fetal bovine serum;
G/F – actin, globular actin /filamentous actin;
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GADD34, Growth Arrest And DNA-Damage-Inducible34
GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
IF, immunofluorescence;
IHC, immunohistochemistry
IKB, I-kappa-B;
IKK, IκB kinase;
KLF4, kruppel like factor 4;
LPS, lipopolysaccharides;
MMP9, matrix metalloproteinase 9
MSX2, muscle segment homeobox 2;
MYH11, smooth muscle myosin heavy chain;
MYOCD, myocardin;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells;
OCN, osteocalcin;
OCT, optimal cutting temperature compound;
PAC1, a pulmonary arterial SMC cell line;
PBS, phosphate-buffered saline;
PERK, PRKR-Like Endoplasmic Reticulum Kinase;
Pit-1, The sodium-dependent phosphate cotransporter;
PP1, Protein phosphatase 1;
PPARγ, Peroxisome proliferator-activated receptor gamma;
PPP1R15A, Protein Phosphatase 1 Regulatory Subunit 15A
rtRT-PCR, real-time RT-PCR;
RUNX2, Runt-related transcription factor 2
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ROS, reactive oxygen species;
SBE, smad binding element;
siRNA, small interfering RNA;
Sm22-/-, Sm22 knockout;
Sm22+/+, Sm22 wild type;
TAGLN 2, transgelin 2
TCE, TGFβ control element
Tg, Thapsigargin;
TUBB, tubulin beta
TUNEL, Terminal deoxynucleotidyl transferase (TdT) dUTP Nick-End Labeling;
UPR, unfolded protein response
UTR, untranslated region;
SMA, smooth muscle α actin;
SMC, smooth muscle cell;
snRNA, small nuclear RNA;
SRF, serum response factor;
VCAM1, vascular cell adhesion molecule 1;
VIM, vimentin;
VSMC, vascular smooth muscle cell;
WB, western blotting.
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ABSTRACT
EFFECT OF ENDOPLASMIC RETICULUM STRESS ON
VASCULAR SMOOTH MUSCLE CELLS AND ITS
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Background: The vascular smooth muscle cells(VSMC) possess the ability to differentiate into a
synthetic phenotype in response to stress. This phenotypic modulation may be accompanied by
inflammatory or osteogenic response in chronic stress. The synthetic state is characterized by low levels
of contractile markers unlike the differentiated state.
Hypothesis: Endoplasmic reticulum (ER) stress causes phenotypic modulation in VSMCs leading to
apoptosis. Many transcription factors induced by ER stress contribute to the downregulation of Sm22α.
Perturbation in cytoskeletal dynamics exacerbates the ER stress response.
Methods: Ex-vivo culture was used to establish importance of Sm22 in ER stress. In vitro analysis was
carried out in PAC1 cells to elucidate the signaling induces by ER stress in smooth muscle cells and its
contribution to the downregulation of Sm22α.
Results: ER stress caused a transient upregulation of smooth muscle markers during 1-6 hrs. of treatment
with the ER stress inducer thapsigargin. The downregulation of contractile markers at 24hour of
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thapsigargin treatment was accompanied by upregulation of phenotypic regulators- Klf4, Mmp9 and Pdgfbb, inflammatory markers Vacm-1 and Ccl-2 and osteogenic markers-Runx2, Msx2, Ocn and Pit-1.
Overexpression of SM22 reduced the expression of ER stress markers (Atf4 and Chop) and inflammation
marker (Ccl-2). Myocardin overexpression could reduce the downregulation of SM22α. Promoter analysis
of Sm22α showed that all the cis acting elements were involved in its downregulation under ER stress. As
our results indicated a protected role of SM22α under ER stress conditions, a drug screen was carried out
to identify potential regulators of Sm22α.The screen identified isoflavonoids as positive regulators for
Sm22α expression. Biochanin A, a candidate from the drug screen was subsequently validated in the
fibroblast cell line
Conclusion: SM22α plays a protective role in the ER stress condition. Many of the ER stress induced
factors associate with different cis acting elements in the Sm22α promoter to repress it. Sm22α could be a
potential drug target to reduce the pathogenic effects of ER stress in cardiovascular diseases. Preliminary
drug screen suggests that the phytoestrogens – flavonoids and isoflavonoids could be potential candidates
with therapeutic benefits.
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